Oxypertine in tardive dyskinesia: an 8-week controlled study
- PMID: 6140973
- DOI: 10.1192/bjp.144.1.48
Oxypertine in tardive dyskinesia: an 8-week controlled study
Abstract
In a double-blind placebo controlled trial of oxypertine in the treatment of tardive dyskinesia, 33 patients with chronic schizophrenia received either oxypertine or placebo. At the end of eight weeks, the results showed that oxypertine was superior to placebo at a statistically significant level.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
